Regulatory approval
Published by the Health Canada.
Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
This is written in the approval document as:
ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Mycosis Fungoides | Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone |